Dr. Harmon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St Yaw 7
Mass General Hospital
Boston, MA 02114Phone+1 617-726-8748Fax+1 617-726-2894
Education & Training
Harvard Medical SchoolClass of 1974
Certifications & Licensure
MA State Medical License 1979 - 2019
Clinical Trials
- Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall Start of enrollment: 2004 Jun 17
Publications & Presentations
PubMed
- Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Yunfei Liao, Lulu Chen, Yong Feng, Jacson Shen, Yan Gao
Oncotarget. 2024-02-05 - Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Yunfei Liao, Slim Sassi, Stefan Halvorsen, Yong Feng, Jacson Shen
Scientific Reports. 2024-01-22 - 1 citationsAuthor Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Yunfei Liao, Slim Sassi, Stefan Halvorsen, Yong Feng, Jacson Shen
Scientific Reports. 2018-08-09
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
